We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

2-Part Multiple Ascending Dose Study for Safety and Pharmacokinetics in Healthy and Elderly Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01673451
Recruitment Status : Completed
First Posted : August 28, 2012
Last Update Posted : October 11, 2013
Information provided by (Responsible Party):

Study Description
Brief Summary:
This is a single-center, randomized, double-blind, placebo-controlled, sequential, multiple-dose study. The study will be conducted in two parts: Part A (6 cohorts of healthy adults receiving evening dosing) and Part B (one cohort of elderly adults receiving evening dosing).

Condition or disease Intervention/treatment Phase
CNS Drug: E2006 Drug: Placebo comparator Phase 1

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of E2006 in Healthy Adult and Elderly Subjects
Study Start Date : August 2012
Primary Completion Date : May 2013
Study Completion Date : July 2013
Arms and Interventions

Arm Intervention/treatment
Placebo Comparator: Placebo comparator Drug: Placebo comparator
E2006-matched placebo (Part A and Part B); Part B: dose level to be determined based on results of Part A, administered as capsules
Experimental: E2006 Drug: E2006
Part A: 2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg, and 75 mg E2006 administered as capsules

Outcome Measures

Primary Outcome Measures :
  1. Incidence of Adverse events (AEs) [ Time Frame: 28 days ]

Secondary Outcome Measures :
  1. Plasma concentrations of E2006 [ Time Frame: Part A up to 288 hours postdose; Part B: up to 324 hours postdose ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes


  • Healthy males or females, ages 18 to 55 years (Part A) or 65 to 80 years (Part B)
  • Who report typical time in bed 7.5 to 9 hours
  • Who report typical bedtime 22:00 - 24:00 and typical wake time 06:00 - 08:00
  • Who report typical sleep latency of <= 30 minutes
  • All females must be of non-childbearing potential, or subjects who have been sterilized surgically or who are otherwise proven sterile. Females must have a negative serum beta-human chorionic gonadotropin (Beta-hCG) test result at Screening and a negative urine pregnancy test at Baseline.
  • Body mass index BMI > 18 and 32 kg/m2 at Screening


  • Performed shift work within 2 weeks prior to Screening
  • Had taken a flight across three or more time zones in the 7 days prior to Screening
  • Female subjects who are nursing
  • With a history of gastrointestinal surgery (hepatectomy, nephrectomy, digestive organ resection, etc.) that may affect PK profile of E2006
  • With a known history of clinically significant drug or food allergies or presently experiencing significant seasonal allergy
  • Hypersensitivity to the study drug or any of the excipients
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01673451

United States, California
Parexel, California Clinical Trials
Culver City, California, United States, 90232
Glendale, California, United States, 91206
Sponsors and Collaborators
Eisai Inc.
Principal Investigator: Dohwa Kim Parexel
More Information

Responsible Party: Eisai Inc.
ClinicalTrials.gov Identifier: NCT01673451     History of Changes
Other Study ID Numbers: E2006-A001-002
First Posted: August 28, 2012    Key Record Dates
Last Update Posted: October 11, 2013
Last Verified: October 2013

Keywords provided by Eisai Inc.: